ZEISS to enhance its portfolio of Surgical Ophthalmology solutions, further positioning the Company as a global innovation leader and solution provider in the full space of ophthalmology.
Carl Zeiss Meditec today announced it has entered into an agreement to acquire IanTECH. Headquartered in Reno, Nevada, IanTECH is a privately held company focused on technology solutions for micro-interventional cataract surgery.
Cataract surgery has been dependent on phaco technology for over 50 years. ZEISS believes that the market needs a fresh innovative approach in the field of phaco. IanTECH’s surgical technology is designed to change the future of managing cataracts. “We expect that IanTECH will complement our leading portfolio of equipment and consumables in cataract surgery, allowing us to offer physicians and patients a new standard of care,” says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec. “The technology has the potential to simplify challenging cases, reduce risk to patients and further improve outcomes while being easy to train and adapt for surgeons.”
“We are pleased to bring the IanTECH team and technology into the ZEISS family,” states James V. Mazzo, Global President Ophthalmic Devices at Carl Zeiss Meditec.
“We look forward to joining ZEISS to combine our efforts in bringing superior technology to the market and we are pleased to align with the great culture and commitment at ZEISS,” adds Brian Walsh, CEO of IanTECH.